// App-Quantinova.ai

S1006 2015 AHA : RVX-208 a Selective Bromodomain and Extra-terminal BET Protein Inhibitor Acts on Several Pathways to Benefit Cardiovascular Risks

Researchers

Presenter

  • Ewelina Kulikowski

Principal Investigators

  • Sylwia Wasiak

  • Dean Gilham

  • Christopher Halliday

  • Kenneth Lebioda

  • Mike Sweeney

  • Jan O Johansson

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Resverlogix Corp.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Venous thrombosis

  • Diabetes

  • Liver cancer

Biomarkers

  • Apolipoprotein A-I

  • Nucleoside diphosphate kinase A

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved